Urology Annals
About UA | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionLogin 
Urology Annals
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 601   Home Print this page  Email this page Small font size Default font size Increase font size
ORIGINAL ARTICLE
Year : 2017  |  Volume : 9  |  Issue : 2  |  Page : 153-158

Reimbursements and frequency of tests in privately insured testicular cancer patients in the United States: Implications to national guidelines


1 Department of Urology, University of Arkansas for Medical Sciences, Arkansas, USA; Department of Urology, Ain Shams University, Cairo, Egypt
2 Department of Urology, University of Arkansas for Medical Sciences, Arkansas, USA
3 Department of Urology, University of California, San Diego, California, USA
4 Department of Urology, Baylor College of Medicine, Michael E. DeBakey Veterans Affairs Hospital, Houston, Texas, USA
5 Department of Urology, Ain Shams University, Cairo, Egypt

Correspondence Address:
Mohamed H Kamel
Department of Urology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205

Login to access the Email id


DOI: 10.4103/0974-7796.204180

PMID: 28479767

Rights and Permissions

Objectives: The objective of this study was to assess the frequency of utilization and reimbursement of the common diagnostic tests and treatment modalities used in testicular cancer care. Methods: LifeLink™ (IMS Health, Danbury, CT, USA) Claims Database was used. We identified 877 subjects with a primary diagnosis of testicular cancer (ICD 186.9) between 2007 and 2012. Median reimbursement and frequency of the diagnostic/treatment modalities used were recorded. Results: The most common claim was a vein puncture with median reimbursement of $9.11. Tumor markers, alpha-fetoprotein and beta human chorionic gonadotropin, were ranked 6th and 7th with median reimbursement of $52.13 and $48.71, respectively. Chest X-ray and computerized tomography (CT) scan of the chest were ranked 9th and 13th with median reimbursement of $68.51 and $769, respectively. A contrast CT scan of abdomen and pelvis was the 11th most frequent claim with median reimbursement of $855.89. The three invasive treatment modalities, chemotherapy, radiation therapy, and retroperitoneal lymphadenectomy were ranked 8th, 15th, and 164th with median reimbursement of $2858.38, $3988.25, and $2009.67, respectively. Conclusions: Testicular cancer is not an inexpensive disease. Surgery is the less utilized than radiation and chemotherapy despite lower cost. This may have implications to national guidelines and training since these treatments often carry the same grade of recommendation.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1789    
    Printed22    
    Emailed0    
    PDF Downloaded145    
    Comments [Add]    

Recommend this journal